The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
|Brand Name Sort descending||Generic Name||Therapeutic Area||Recommendation Type||Project Status||Date Submission Received||Date Recommendation Issued|
|Zytiga||Abiraterone acetate||Metastatic Castration Resistant Prostate Cancer||Reimburse with clinical criteria and/or conditions||Complete|
|Zytiga (Resubmission)||Abiraterone||Prostate Cancer Resubmission||Withdrawn|
|Zytram XL||Tramadol hydrochloride||Pain, acute||Withdrawn|
|Zytram XL||Tramadol hydrochloride||Pain, acute||Do not list||Complete|